All In Biotech

Drug Trial Radar · NCT06637423

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Dec 20, 2024

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

Conditions

  • Non-Muscle Invasive Bladder Cancer

Interventions

  • Sacituzumab tirumotecanDrug

    Intravesical administration

  • Rescue medicationDrug

    Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

  • Supportive care measuresDrug

    Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to approximately 7 weeks
  2. Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to approximately 10 weeks
  3. Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)Time frame: Up to approximately 6 weeks

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Michael G Oefelein Clinical Trials ( Site 0053)

    Bakersfield, California

  • Moffitt Cancer Center ( Site 0057)

    Tampa, Florida

  • Northwestern University ( Site 0051)

    Chicago, Illinois

  • Johns Hopkins University ( Site 0055)

    Baltimore, Maryland

  • Princess Margaret Cancer Centre ( Site 0003)

    Toronto, Ontario, Canada

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002)

    Sherbrooke, Quebec, Canada

  • Hôpital Claude Huriez ( Site 0012)

    Lille, Nord, France

  • HENRI MONDOR HOSPITAL ( Site 0011)

    Créteil, Val-de-Marne, France

  • Gustave Roussy ( Site 0013)

    Villejuif, Val-de-Marne, France

  • Erasmus Medisch Centrum ( Site 0032)

    Rotterdam, South Holland, Netherlands

  • Hospital Universitario 12 de Octubre ( Site 0042)

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria ( Site 0043)

    Málaga, Andalusia, Spain

  • St Bartholomew s Hospital ( Site 0061)

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.